(Total Views: 537)
Posted On: 05/31/2025 1:21:33 AM
Post# of 154111
Tripathy's work has contributed to the approval of several drugs for breast cancer, including:
Enhertu (fam-trastuzumab deruxtecan-nxki):
This drug was approved for HER2-low breast cancer, a type of breast cancer where the HER2 protein is present at low levels.
Olaparib:
This PARP inhibitor was approved for the treatment of patients with BRCA-positive, HER2-negative metastatic breast cancer.
*Astrazenaca & Merk owned.
*LL video also mentions is PARP compatiable
Sacituzumab govitecan-hziy (Trodelvy):
This drug is used in the treatment of triple-negative breast cancer.
Atezolizumab (Tecentriq):
This immunotherapy agent is used in combination with chemotherapy for triple-negative breast cancer.
___
Now he's teamed with the future game changer --- & the drug which will be New SOC's.
Enhertu (fam-trastuzumab deruxtecan-nxki):
This drug was approved for HER2-low breast cancer, a type of breast cancer where the HER2 protein is present at low levels.
Olaparib:
This PARP inhibitor was approved for the treatment of patients with BRCA-positive, HER2-negative metastatic breast cancer.
*Astrazenaca & Merk owned.
*LL video also mentions is PARP compatiable
Sacituzumab govitecan-hziy (Trodelvy):
This drug is used in the treatment of triple-negative breast cancer.
Atezolizumab (Tecentriq):
This immunotherapy agent is used in combination with chemotherapy for triple-negative breast cancer.
___
Now he's teamed with the future game changer --- & the drug which will be New SOC's.
(9)
(0)
